董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chee Keong Yap | 男 | Independent Director | 70 | 未披露 | 未持股 | 2026-04-14 |
| Jook Yuen Low | 女 | Independent Director | 48 | 未披露 | 0.13 | 2026-04-14 |
| Muhammad Azrul bin Abdul Hamid | 男 | Independent Director | 51 | 未披露 | 未持股 | 2026-04-14 |
| Su Leng Tan Lee | 男 | Chief Executive Officer and Director and President | 42 | 44.60万美元 | 未持股 | 2026-04-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Su Leng Tan Lee | 男 | Chief Executive Officer and Director and President | 42 | 44.60万美元 | 未持股 | 2026-04-14 |
| Set Fui Chong | 女 | Chief Financial Officer | 62 | 2.27万美元 | 未持股 | 2026-04-14 |
董事简历
中英对照 | 中文 | 英文- Chee Keong Yap
-
Chee Keong Yap自2022年3月起担任公司董事，担任审核委员会主席，并为苏格兰特许会计师协会会员。过去，他曾担任Niche Capital Emas Holdings Bhd的董事总经理兼执行董事，以及Bumiputra Merchant Bankers Bhd的首席执行官兼执行董事。Yap先生拥有英国利兹大学经济学文学士（一级荣誉）学位（1978年）。他曾于1978年至1981年在英国从事审计工作。Yap先生还在vario私营公司的董事会任职。
Chee Keong Yap has been a Director of the Company since March 2022, serving as the Audit Committee Chairman, a member of the Compensation Committee, and is a Member of The Institute of Chartered Accountants of Scotland. In the past he was Managing Director & Executive Director at Niche Capital Emas Holdings Bhd and Chief Executive Officer & Executive Director at Bumiputra Merchant Bankers Bhd. Mr. Yap holds a Bachelor of Arts (First Class Honours) degree in Economics from the University of Leeds, United Kingdom (1978). He has auditing experience in England from 1978 to 1981. - Chee Keong Yap自2022年3月起担任公司董事，担任审核委员会主席，并为苏格兰特许会计师协会会员。过去，他曾担任Niche Capital Emas Holdings Bhd的董事总经理兼执行董事，以及Bumiputra Merchant Bankers Bhd的首席执行官兼执行董事。Yap先生拥有英国利兹大学经济学文学士（一级荣誉）学位（1978年）。他曾于1978年至1981年在英国从事审计工作。Yap先生还在vario私营公司的董事会任职。
- Chee Keong Yap has been a Director of the Company since March 2022, serving as the Audit Committee Chairman, a member of the Compensation Committee, and is a Member of The Institute of Chartered Accountants of Scotland. In the past he was Managing Director & Executive Director at Niche Capital Emas Holdings Bhd and Chief Executive Officer & Executive Director at Bumiputra Merchant Bankers Bhd. Mr. Yap holds a Bachelor of Arts (First Class Honours) degree in Economics from the University of Leeds, United Kingdom (1978). He has auditing experience in England from 1978 to 1981.
- Jook Yuen Low
-
Jook Yuen Low自2024年11月起担任公司董事，同时也是审计委员会和提名与企业管治委员会的成员。她拥有亚特兰大昆士兰科技大学的法学学士（法学学士）和公共关系专业BINSE硕士学位。2004年，她作为马来亚高等CT的倡导者和律师获得律师资格。目前，Low女士是Azura Mokhtar & Low律师事务所的合伙人。她的法律生涯跨越了20多年，在此期间，她在产权转让、公司法和alth管理咨询方面积累了丰富的经验。
Jook Yuen Low has been a Director of the Company since November 5, 2024, and also is a member of the Audit Committee and the Nominating and Corporate Governance Committee. She holds a Bachelor of Laws (LLB) and a Master of Business in Public Relations from the Queensland University of Technology, Australia. She was called to the Bar as an Advocate & Solicitor of the High Court of Malaya in 2004. Currently, Ms. Low is a partner at the law firm Azura Mokhtar & Low. Her legal career spans over 20 years, during which she has gained substantial experience in conveyancing, corporate law, and wealth management consulting. - Jook Yuen Low自2024年11月起担任公司董事，同时也是审计委员会和提名与企业管治委员会的成员。她拥有亚特兰大昆士兰科技大学的法学学士（法学学士）和公共关系专业BINSE硕士学位。2004年，她作为马来亚高等CT的倡导者和律师获得律师资格。目前，Low女士是Azura Mokhtar & Low律师事务所的合伙人。她的法律生涯跨越了20多年，在此期间，她在产权转让、公司法和alth管理咨询方面积累了丰富的经验。
- Jook Yuen Low has been a Director of the Company since November 5, 2024, and also is a member of the Audit Committee and the Nominating and Corporate Governance Committee. She holds a Bachelor of Laws (LLB) and a Master of Business in Public Relations from the Queensland University of Technology, Australia. She was called to the Bar as an Advocate & Solicitor of the High Court of Malaya in 2004. Currently, Ms. Low is a partner at the law firm Azura Mokhtar & Low. Her legal career spans over 20 years, during which she has gained substantial experience in conveyancing, corporate law, and wealth management consulting.
- Muhammad Azrul bin Abdul Hamid
-
Muhammad Azrul bin Abdul Hamid自2023年12月起担任公司董事，在马来西亚高等法院和马来西亚上诉法院的一系列事务中拥有超过20年的律师经验，涉及知识产权索赔、合同事项、债务催收和tortio索赔。Azrul先生还拥有为技术工业提供咨询服务、就知识产权保护和执法事项提供建议的经验。Azrul先生曾就公共政策和政府参与的多个方面向客户提供建议，包括与政府机构和地方当局就初创企业、中小企业和跨国公司的biness相关问题打交道。Azrul先生是马来西亚Eurocham知识产权委员会、吉隆坡律师协会IT委员会和律师协会CyberLaw委员会的成员。他是东南亚欧盟中小企业知识产权服务台的撰稿人和定期发言人。阿兹鲁尔还在多家私营公司的董事会任职。
Muhammad Azrul bin Abdul Hamid has been a director of the Company since December 11, 2023. He is a member of the Audit Committee and is Chairman of the Nominating and Corporate Governance Committee, and the Compensation Committee. He has more than 20 years of experience as a lawyer in a range of matters at the Malaysian High Court and the Malaysian Court of Appeal involving IP claims, contractual matters, debt collection and tortious claims. Mr. Azrul also has experience in providing advisory services for the technology industry, providing advice on intellectual property protection and enforcement matters. Mr. Azrul has advised clients on the multiple facets of public policy and government engagement, including dealing with government agencies and local authorities in relation to business related issues for start ups, small and medium enterprises, and multinational corporations. Mr. Azrul is a member of the Malaysian Eurocham IP Committee, Kuala Lumpur Bar Committee IT Committee, and Bar Council Cyberlaw Committee. He is a contributor and regular speaker for the South East Asia EU SME IPR Helpdesk. - Muhammad Azrul bin Abdul Hamid自2023年12月起担任公司董事，在马来西亚高等法院和马来西亚上诉法院的一系列事务中拥有超过20年的律师经验，涉及知识产权索赔、合同事项、债务催收和tortio索赔。Azrul先生还拥有为技术工业提供咨询服务、就知识产权保护和执法事项提供建议的经验。Azrul先生曾就公共政策和政府参与的多个方面向客户提供建议，包括与政府机构和地方当局就初创企业、中小企业和跨国公司的biness相关问题打交道。Azrul先生是马来西亚Eurocham知识产权委员会、吉隆坡律师协会IT委员会和律师协会CyberLaw委员会的成员。他是东南亚欧盟中小企业知识产权服务台的撰稿人和定期发言人。阿兹鲁尔还在多家私营公司的董事会任职。
- Muhammad Azrul bin Abdul Hamid has been a director of the Company since December 11, 2023. He is a member of the Audit Committee and is Chairman of the Nominating and Corporate Governance Committee, and the Compensation Committee. He has more than 20 years of experience as a lawyer in a range of matters at the Malaysian High Court and the Malaysian Court of Appeal involving IP claims, contractual matters, debt collection and tortious claims. Mr. Azrul also has experience in providing advisory services for the technology industry, providing advice on intellectual property protection and enforcement matters. Mr. Azrul has advised clients on the multiple facets of public policy and government engagement, including dealing with government agencies and local authorities in relation to business related issues for start ups, small and medium enterprises, and multinational corporations. Mr. Azrul is a member of the Malaysian Eurocham IP Committee, Kuala Lumpur Bar Committee IT Committee, and Bar Council Cyberlaw Committee. He is a contributor and regular speaker for the South East Asia EU SME IPR Helpdesk.
- Su Leng Tan Lee
-
Su Leng Tan Lee自2023年12月起担任公司董事，在信息系统、酒店、投资管理、建筑、物业开发、旅行、政府联络和生命科学等多个行业拥有超过20年的丰富经验，主要专注于商业化、财务和一般管理。自2023年8月起，Tan先生担任公司首席运营官，随后担任公司首席执行官。自2022年5月起，Tan先生担任Dryox Health Limited的首席商务官，这是一家专注于为皮肤病学领域未满足的需求重新利用药物的初创公司，特别是抗胆碱能药物。自2017年8月起，Tan先生担任FLO生命科学集团的所有者和董事总经理，专注于感染疾病和肿瘤学临床前候选药物以及临床研究。从2018年7月至2019年4月，Tan先生担任Avillion Berhad的总裁，该公司是一家公开上市的旅游和酒店集团，拥有酒店、商业物业和入境/出境旅游服务。Tan还担任vario私营公司的董事会成员。
Su Leng Tan Lee has been the Chief Executive Officer of the Company since December 11, 2023, and was appointed President of the Company on November 5, 2024. Previously, Mr. Tan Lee was the Company's Chief Operating Officer from August 2023 until December 11, 2023. Mr. Tan Lee has over 20 years of extensive experience in a variety of industries, including information systems, hospitality, investment management, construction, property development, travel, government liaison, and life sciences, primarily focused on commercialization, finance, and general management. From May 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From August 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group's owner and Managing Director, focusing on infectious diseases and oncology pre clinical drug candidates and clinical research. From July 2018 to April 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services. - Su Leng Tan Lee自2023年12月起担任公司董事，在信息系统、酒店、投资管理、建筑、物业开发、旅行、政府联络和生命科学等多个行业拥有超过20年的丰富经验，主要专注于商业化、财务和一般管理。自2023年8月起，Tan先生担任公司首席运营官，随后担任公司首席执行官。自2022年5月起，Tan先生担任Dryox Health Limited的首席商务官，这是一家专注于为皮肤病学领域未满足的需求重新利用药物的初创公司，特别是抗胆碱能药物。自2017年8月起，Tan先生担任FLO生命科学集团的所有者和董事总经理，专注于感染疾病和肿瘤学临床前候选药物以及临床研究。从2018年7月至2019年4月，Tan先生担任Avillion Berhad的总裁，该公司是一家公开上市的旅游和酒店集团，拥有酒店、商业物业和入境/出境旅游服务。Tan还担任vario私营公司的董事会成员。
- Su Leng Tan Lee has been the Chief Executive Officer of the Company since December 11, 2023, and was appointed President of the Company on November 5, 2024. Previously, Mr. Tan Lee was the Company's Chief Operating Officer from August 2023 until December 11, 2023. Mr. Tan Lee has over 20 years of extensive experience in a variety of industries, including information systems, hospitality, investment management, construction, property development, travel, government liaison, and life sciences, primarily focused on commercialization, finance, and general management. From May 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From August 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group's owner and Managing Director, focusing on infectious diseases and oncology pre clinical drug candidates and clinical research. From July 2018 to April 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.
高管简历
中英对照 | 中文 | 英文- Su Leng Tan Lee
Su Leng Tan Lee自2023年12月起担任公司董事，在信息系统、酒店、投资管理、建筑、物业开发、旅行、政府联络和生命科学等多个行业拥有超过20年的丰富经验，主要专注于商业化、财务和一般管理。自2023年8月起，Tan先生担任公司首席运营官，随后担任公司首席执行官。自2022年5月起，Tan先生担任Dryox Health Limited的首席商务官，这是一家专注于为皮肤病学领域未满足的需求重新利用药物的初创公司，特别是抗胆碱能药物。自2017年8月起，Tan先生担任FLO生命科学集团的所有者和董事总经理，专注于感染疾病和肿瘤学临床前候选药物以及临床研究。从2018年7月至2019年4月，Tan先生担任Avillion Berhad的总裁，该公司是一家公开上市的旅游和酒店集团，拥有酒店、商业物业和入境/出境旅游服务。Tan还担任vario私营公司的董事会成员。
Su Leng Tan Lee has been the Chief Executive Officer of the Company since December 11, 2023, and was appointed President of the Company on November 5, 2024. Previously, Mr. Tan Lee was the Company's Chief Operating Officer from August 2023 until December 11, 2023. Mr. Tan Lee has over 20 years of extensive experience in a variety of industries, including information systems, hospitality, investment management, construction, property development, travel, government liaison, and life sciences, primarily focused on commercialization, finance, and general management. From May 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From August 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group's owner and Managing Director, focusing on infectious diseases and oncology pre clinical drug candidates and clinical research. From July 2018 to April 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.- Su Leng Tan Lee自2023年12月起担任公司董事，在信息系统、酒店、投资管理、建筑、物业开发、旅行、政府联络和生命科学等多个行业拥有超过20年的丰富经验，主要专注于商业化、财务和一般管理。自2023年8月起，Tan先生担任公司首席运营官，随后担任公司首席执行官。自2022年5月起，Tan先生担任Dryox Health Limited的首席商务官，这是一家专注于为皮肤病学领域未满足的需求重新利用药物的初创公司，特别是抗胆碱能药物。自2017年8月起，Tan先生担任FLO生命科学集团的所有者和董事总经理，专注于感染疾病和肿瘤学临床前候选药物以及临床研究。从2018年7月至2019年4月，Tan先生担任Avillion Berhad的总裁，该公司是一家公开上市的旅游和酒店集团，拥有酒店、商业物业和入境/出境旅游服务。Tan还担任vario私营公司的董事会成员。
- Su Leng Tan Lee has been the Chief Executive Officer of the Company since December 11, 2023, and was appointed President of the Company on November 5, 2024. Previously, Mr. Tan Lee was the Company's Chief Operating Officer from August 2023 until December 11, 2023. Mr. Tan Lee has over 20 years of extensive experience in a variety of industries, including information systems, hospitality, investment management, construction, property development, travel, government liaison, and life sciences, primarily focused on commercialization, finance, and general management. From May 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From August 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group's owner and Managing Director, focusing on infectious diseases and oncology pre clinical drug candidates and clinical research. From July 2018 to April 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.
- Set Fui Chong
Set Fui Chong拥有超过25年的高级财务领导经验，包括自2013年起担任Avillion Berhad的首席财务官至2024年11月。她是马来西亚会计师协会（MIA）和特许公认会计师协会（ACCA）的成员。
Set Fui Chong has over 25 years of Senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the of the Malaysia Institute of Accountants (MIA) and Association of Chartered Certified Accountants (ACCA).- Set Fui Chong拥有超过25年的高级财务领导经验，包括自2013年起担任Avillion Berhad的首席财务官至2024年11月。她是马来西亚会计师协会（MIA）和特许公认会计师协会（ACCA）的成员。
- Set Fui Chong has over 25 years of Senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the of the Malaysia Institute of Accountants (MIA) and Association of Chartered Certified Accountants (ACCA).